Differentiation-dependent modulation of TNF production by PAF in human HL-60 myeloid leukemia cells.
Platelet-activating factor (PAF) can augment tumor necrosis factor (TNF) production by human monocytes in a bimodal manner, with two peaks of activation at picomolar and micromolar concentrations. These peaks are partially associated with monocyte subsets presenting different characteristics in terms of size, density, phenotypic markers, and [Ca2+]i mobilization responses. In the present study, we used the human promyelocytic leukemia cell line HL-60, at various times during differentiation with 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] toward the monocyte lineage, in order to study the relation of cell differentiation to responsiveness to PAF in terms of cytokine production. TNF production was induced by pretreatment with interferon gamma for 24 h and treatment with muramyl dipeptide. Although detectable TNF was produced by 4 day-differentiated cells, no effect was seen with PAF (10(-16)-10(-6) M) at this or earlier stages. In contrast, 5 day-differentiated cells had a comparable baseline production of TNF but responded with a 2.5-fold increase to PAF with a single peak, maximal at 10(-8) M. Moreover, 6 day- or 7 day-differentiated HL-60 cells showed a further increase in TNF production in response to PAF, and the response was bimodal, similar to that of the less dense subset of monocytes, with peaks at 10(-14) and 10(-7) M PAF. In parallel, undifferentiated HL-60 failed to respond to PAF in terms of [Ca2+]i mobilization. The earliest responsiveness to PAF (10(-7) M) was observed by 4 days of treatment with 1,25(OH)2D3, and by day 7 the response to PAF became bimodal (10(-14) and 10(-7) M). These results indicate that myeloid cells acquire, during maturation toward the monocyte lineage, a progressive responsiveness to PAF in terms of [Ca2+]i mobilization and enhanced cytokine production, and they suggest that the heterogeneity in responses to PAF observed in normal monocytes may be related to their stage of differentiation or maturation.
Rola-Pleszczynski
M
M
Department of Pediatrics, Faculty of Medicine, University of Sherbrooke, Québec, Canada.
Stankova
J
J
D002117:Calcitriol / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002454:Cell Differentiation; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000378:metabolism* / Q000473:pathology; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D012333:RNA, Messenger / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis* / Q000235:genetics
D010972:Platelet Activating Factor; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D002117:Calcitriol; D002118:Calcium